High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer

摘要: Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with poor prognosis in primary breast cancer and several other types. In the present study, we have measured ELISA levels of VEGF cytosolic extracts 845 tumors patients who developed recurrence during follow-up. All received tamoxifen (n = 618) or cyclophosphamide, methotrexate, 5-fluorouracil (CMF) 5-fluorouracil, Adriamycin, cyclophosphamide (FAC) chemotherapy 227) as first-line systemic therapy after diagnosis advanced disease. were not related age menopausal status but negatively estrogen receptor progesterone (P < 0.0001). relapsed within 1 year surgery, tumor higher than showed longer disease-free interval 0.0005). first relapse viscera, compared those that bone soft tissue 0.0004). univariate analysis for response therapy, high intermediate rate response, low tumor-VEGF Similarly, multivariate treatment, corrected age, site relapse, interval, status, was an independent predictive 0.009). concordance, short progression-free survival postrelapse overall (both, P On chemotherapy, decreased VEGF, both 0.003) 0.004). Furthermore, 0.001). conclusion, level is important marker predicts efficacy cancer. Knowledge might helpful selecting individual may benefit from treatments antiangiogenic agents combined conventionally used drugs.